Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659815 | 0.89 | ALDH1A1 (0.40) | ALDH1A1POLBL3MBTL1MAPTMEN1 | |
| SCHEMBL2536617 | 0.86 | ALDH1A1 (0.41) | ALDH1A1POLBL3MBTL1MAPTMEN1 | |
| SCHEMBL29365100 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBL3MBTL1MAPTKMT2A | |
| SCHEMBL21597029 | 0.83 | KDM1A (0.43) | ALDH1A1POLBL3MBTL1MAPTMEN1 | |
| SCHEMBL29703386 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBL3MBTL1MAPTKMT2A | |
| SCHEMBL23885388 | 0.83 | ALDH1A1 (0.40) | ALDH1A1POLBL3MBTL1MAPTMEN1 | |
| SCHEMBL30053965 | 0.83 | ALDH1A1 (0.40) | ALDH1A1POLBL3MBTL1MAPTMEN1 | |
| SCHEMBL1529272 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBL3MBTL1MAPTKMT2A | |
| SCHEMBL275963 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBL3MBTL1MAPTKMT2A | |
| SCHEMBL5519306 | 0.82 | MAPT (0.50) | ALDH1A1POLBL3MBTL1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4125874-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335046-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4081199-A2 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20130116238-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
| CN-103038214-A | Process for preparing cycloalkylcarboxamido-indole compounds | VERTEX PHARMA | 2013-04-10 | — | — | CN | disclosed |
| EP-2560954-A2 | PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| CN-102892764-A | Solid forms of -1(2, 2-difluorobenzo [ D ] [1,3] dioxol-5-yl) -N- (1- (2, 3-dihydroxypropyl) -6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl) -1H-indol-5-yl) cyclopropanecarboxamide | VERTEX PHARMA | 2013-01-23 | — | — | CN | disclosed |
| WO-2012170061-A1 | FORMULATIONS OF (R)-1-(2,2-DIFLUROBENZO[D][1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYL PROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012027247-A2 | PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEROF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20120046330-A1 | PHARMACEUTICAL COMPOSITIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011133751-A9 | PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120015999-A1 | FORMULATIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011133751-A2 | PROCESS OF PRODUCING CYCLOALKYLCARBOXAMIDO-INDOLE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116238-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 1961/4885POLB 2183/4885L3MBTL1 3601/4885 |
| US-20120015999-A1 | FORMULATIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE | HTR1A, HTR1D, HTR1B | ALDH1A1 90/4885POLB 1985/4885L3MBTL1 4727/4885 |
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX5 | ALDH1A1 203/4885POLB 1414/4885L3MBTL1 1807/4885 |
| US-20120046330-A1 | PHARMACEUTICAL COMPOSITIONS OF (R)-1-(2,2-DIFLUOROBENZO[D] [1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF | CFTR, GLI2, HTR1D | ALDH1A1 463/4885POLB 2234/4885L3MBTL1 3594/4885 |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | ALDH1A1 133/4885POLB 1410/4885L3MBTL1 1916/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885POLB 3588/4885L3MBTL1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.